Intelligent Bio Solutions (NASDAQ: IBNS) belongs to the life sciences sector. This firm works on creating real-time, non-invasive tracking and diagnostic procedures for patients and primary care providers. The INBS stock price stands at $1.21, showing an increase of 7%.

Furthermore, Intelligent Bio Solutions is divided into two segments: The Commercially Available Intelligent Fingerprinting Products, and the Development Stage Saliva Glucose Biosensor Platform (SGBP). The latter is part of the company’s product portfolio, a portable drug screening system that uses a single cartridge and portable handheld reader to analyse fingerprint sweat. 

Other products include a range of biosensor-based Point of Care diagnostic tests (POCT) that the team develops in clinical chemistry, tumor markers, immunology, allergens, and endocrinology. 

The Saliva Glucose Biosensor (SGB), a POCT that will likely replace invasive finger-prick blood glucose tracking for diabetic patients, is the firm’s product candidate, as well. With the aid of INBS’ Biosensor Platform, researchers can detect multiple biological analytes.

This company was established in 2016 and has its main office in New York. In October 2022, the business changed its name from GBS to Intelligent Bio Solutions. 

Furthermore, Life Science Biosensor Diagnostics Pty Ltd, the parent company of Intelligent Bio Solutions Inc., focuses on the development and commercialisation of innovative diagnostic technologies, particularly those that enable non-invasive, real-time monitoring of biomarkers. The company aims to revolutionise medical diagnostics by introducing wearable biosensors that can provide accurate and continuous health data, contributing to personalised medicine and better health outcomes.

INBS Stock Forecast

According to the current INBS stock forecast, by August 17, 2024, the worth of Intelligent Bio Solutions stocks will increase by 18.76% to $1.335997 per share. 

The technical indicators indicate that the current mood is bearish, and the Fear & Greed Index reads 39 (Fear). During the previous 30 days, the volatility of INBS stock price was 17.22%, with 8 out of 30 (or 27%) green days. 

Furthermore, INBS stock prediction is 15.79% higher than the shares’ current price. The stock is trading below the analysts’ estimate, suggesting it might be undervalued. Thus, now is an excellent time to purchase this asset. 

Presuming that Intelligent Bio Solutions shares will grow at the same average annual rate as they have for the past ten years, the INBS stock forecast 2025 currently is $0.467901. Moreover, if the price hit this figure, it would mean 58.41% increase.

Furthermore, if the Intelligent Bio Solutions stock grows at its current 10-year average rate, it will reach $0.005823 in 2030. The INBS stock will increase by 99.48% from its current price if this 2030 stock prediction comes true.

INBS Stock News Today: Learn Important Statistics

Previous Close: 1.1600
Open: 1.1900
Bid: 1.0900 x 100
Ask: 1.1500 x 100
Day’s Range: 1.1200 – 1.1900
Market Cap: 3.491M
Profit Margin: 0.00%
Operating Margin: -358.55%
Return on Assets: -45.62%
Return on Equity: -118.96%
Revenue: 2.83M
Revenue Per Share: 3.29
Quarterly Revenue Growth: 80.20%
EBITDA: -9.25M
Net Income Avi to Common: -10.03M
Diluted EPS: -29.5600
Beta (5Y Monthly): 4.69
52 Week Range: -94.57%
S&P 500 52-Week Change: 19.03%
52 Week High: 24.0000
52 Week Low: 1.0600
50-Day Moving Average: 1.7574
200-Day Moving Average: 3.1969
Average Vol (3 month): 66.78k
Average Vol (10 day): 49.85k
Shares Outstanding: 3.12M
Implied Shares Outstanding: 3.12M
Float: 2.88M

INBS/USD 5-Day Chart

Intelligent Bio Solutions News

Intelligent Bio Solutions has announced major operational advancements recently. Propelled largely by a surge in product sales, the company reported an 80% increase in revenue for its third quarter of fiscal 2024 and a 193% rise for the 9 months ending March 31, 2024.

Additionally, the business established a fresh alliance with a significant European transportation provider to introduce its Intelligent Fingerprinting Drug Screening System to the United Kingdom.

Thanks to these advancements, Intelligent Bio Solutions increased the number of retail establishments it serves in the UK by demonstrating its biometric drug screening device to three significant British retailers. 

Moreover, through a private equity transaction, the company raised about $10.1 million in funding, which it will use to advance its clinical trials and market expansion initiatives.

Industry leaders showed great interest in the company’s drug screening technology when it was shown at The Health & Safety Event 2024 in the UK. Analysts expect all these developments to bolster INBS stock price. 

Additionally, Intelligent Bio Solutions expanded its intellectual property portfolio across 17 European countries by issuing a new European patent for its DSR-Plus Cartridge Reader. 

The board decided to cut from five to four partners after Lawrence Fisher, a board member, passed away. However, the company’s board approved significant pay increases for CFO Spiro Sakiris and CEO Harry Simeonidis.  

This news means that the INBS stock has the potential to gain in the coming months, but only if the company manages to maintain its current standing on the market. Stay tuned to follow the financial world developments on our website.